Craig M. Goodwin

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Adrienne D. Cox · 9 shared papers, 2020–2026 · strength 1.27
   • Paper CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer. DOI 10.1158/0008-5472.can-25-1835↗
   • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
   • Paper VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target… DOI 10.18632/genesandcancer.231↗
2. Channing J. Der · 9 shared papers, 2020–2026 · strength 1.27
   • Paper CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer. DOI 10.1158/0008-5472.can-25-1835↗
   • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
   • Paper VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target… DOI 10.18632/genesandcancer.231↗
3. Clint A. Stalnecker · 7 shared papers, 2021–2026 · strength 1.02
   • Paper CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer. DOI 10.1158/0008-5472.can-25-1835↗
   • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
   • Paper VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target… DOI 10.18632/genesandcancer.231↗
4. Kirsten L. Bryant · 6 shared papers, 2020–2026 · strength 0.82
   • Paper CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer. DOI 10.1158/0008-5472.can-25-1835↗
   • Paper VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target… DOI 10.18632/genesandcancer.231↗
   • Paper Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. DOI 10.1158/0008-5472.can-22-0391↗
5. Andrew M. Waters · 6 shared papers, 2020–2026 · strength 0.79
   • Paper CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer. DOI 10.1158/0008-5472.can-25-1835↗
   • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
   • Paper Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. DOI 10.1158/0008-5472.can-22-0391↗
6. Jennifer E. Klomp · 6 shared papers, 2020–2026 · strength 0.76
   • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
   • Paper VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target… DOI 10.18632/genesandcancer.231↗
   • Paper Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. DOI 10.1158/0008-5472.can-22-0391↗
7. Bjoern Papke · 6 shared papers, 2020–2026 · strength 0.71
   • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
   • Paper Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. DOI 10.1158/0008-5472.can-22-0391↗
   • Paper Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. DOI 10.1158/0008-5472.can-21-1443↗
8. J. Nathaniel Diehl · 5 shared papers, 2020–2026 · strength 0.62
   • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
   • Paper Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer. DOI 10.1016/bs.acr.2021.07.008↗
   • Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060↗
9. A. Cole Edwards · 4 shared papers, 2021–2026 · strength 0.62
   • Paper CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer. DOI 10.1158/0008-5472.can-25-1835↗
   • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
   • Paper Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. DOI 10.1158/0008-5472.can-21-1443↗
10. Andrew J. Aguirre · 4 shared papers, 2020–2026 · strength 0.57
    • Paper CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer. DOI 10.1158/0008-5472.can-25-1835↗
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2021.109291↗
11. G. Aaron Hobbs · 4 shared papers, 2020–2026 · strength 0.57
    • Paper CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer. DOI 10.1158/0008-5472.can-25-1835↗
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2021.109291↗
12. Priya S. Hibshman · 3 shared papers, 2021–2026 · strength 0.45
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
    • Paper Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer. DOI 10.1016/bs.acr.2021.07.008↗
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2021.109291↗
13. Mariaelena Pierobon · 4 shared papers, 2020–2023 · strength 0.43
    • Paper Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. DOI 10.1158/0008-5472.can-22-0391↗
    • Paper Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. DOI 10.1158/0008-5472.can-21-1443↗
    • Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060↗
14. Jonathan M. DeLiberty · 3 shared papers, 2020–2022 · strength 0.30
    • Paper Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. DOI 10.1158/0008-5472.can-21-1443↗
    • Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060↗
    • Paper Atypical KRAS G12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-19-1006↗
15. Emanuel F. Petricoin · 3 shared papers, 2020–2022 · strength 0.30
    • Paper Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. DOI 10.1158/0008-5472.can-21-1443↗
    • Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060↗
    • Paper Atypical KRAS G12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-19-1006↗
16. Devon R. Blake · 2 shared papers, 2021–2026 · strength 0.28
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2021.109291↗
17. William C. Hahn · 2 shared papers, 2021–2026 · strength 0.28
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2021.109291↗
18. Lee M. Graves · 2 shared papers, 2021–2026 · strength 0.28
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2021.109291↗
19. Tikvah K. Hayes · 2 shared papers, 2021–2026 · strength 0.28
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2021.109291↗
20. Ye S. Lee · 2 shared papers, 2021–2023 · strength 0.27
    • Paper VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target… DOI 10.18632/genesandcancer.231↗
    • Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060↗
21. Kristina Drizyte‐Miller · 2 shared papers, 2021–2023 · strength 0.23
    • Paper Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. DOI 10.1158/0008-5472.can-22-0391↗
    • Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060↗
22. Szu-Aun Lim · 1 shared paper, 2026 · strength 0.21
    • Paper CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer. DOI 10.1158/0008-5472.can-25-1835↗
23. Julien Dilly · 1 shared paper, 2026 · strength 0.21
    • Paper CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer. DOI 10.1158/0008-5472.can-25-1835↗
24. Syed Arif Ahmad · 1 shared paper, 2026 · strength 0.21
    • Paper CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer. DOI 10.1158/0008-5472.can-25-1835↗
25. Sarah E. Ackermann · 1 shared paper, 2026 · strength 0.21
    • Paper CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer. DOI 10.1158/0008-5472.can-25-1835↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.